Jason Zemansky
Stock Analyst at B of A Securities
(3.80)
# 635
Out of 4,846 analysts
32
Total ratings
71.43%
Success rate
39.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Neutral | $62 → $54 | $31.21 | +73.02% | 4 | Apr 15, 2025 | |
| INSM Insmed | Maintains: Buy | $92 → $96 | $71.69 | +33.91% | 9 | Mar 20, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $9.22 | +84.38% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $6.30 | +360.32% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $10.98 | +182.33% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $0.92 | +172.15% | 5 | Jun 20, 2024 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $10 | $1.20 | +736.82% | 4 | May 12, 2023 |
Cytokinetics
Apr 15, 2025
Maintains: Neutral
Price Target: $62 → $54
Current: $31.21
Upside: +73.02%
Insmed
Mar 20, 2025
Maintains: Buy
Price Target: $92 → $96
Current: $71.69
Upside: +33.91%
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $9.22
Upside: +84.38%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $6.30
Upside: +360.32%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $10.98
Upside: +182.33%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $0.92
Upside: +172.15%
Werewolf Therapeutics
May 12, 2023
Maintains: Buy
Price Target: $9 → $10
Current: $1.20
Upside: +736.82%